asset acquisition

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage. 

The deal, completed this month with cash reserves for an undisclosed price, adds scalability and multi-omics analysis to Qiagen's bioinformatics portfolio.

Identigene sells in-home DNA paternity test collection kits, while DNA Diagnostics conducts DNA testing for various applications, such as paternity and forensics. 

Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.

The company purchased Tute in a stock-based transaction that closed last month.

The diagnostics provider said it has paid $250,000 for assets comprised of promissory notes, Series A and Series B stock, and intellectual property.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.